New therapy helps boy with rare disease

By Julie Steenhuysen

CHICAGO (Reuters) - A drug used to suppress the immune system in cancer and rheumatoid arthritis has helped extend the life of a Minnesota boy struggling with a rare and deadly form of the genetic disorder Pompe disease.

A team of researchers led by Dr. Nancy Mendelsohn of Children’s Hospitals and Clinics of Minnesota used a novel treatment plan using Rituxan, or rituximab, a drug used for non-Hodgkin’s lymphoma and rheumatoid arthritis made by Genentech Inc and Biogen Idec.

Rituxan is a monoclonal antibody, a genetically engineered immune system molecule. The team used Rituxan in combination with the rheumatoid arthritis drug methotrexate and intravenous gamma globulin, in a bid to damp down the child’s immune response.

“It seems to have worked,” said Mendelsohn, who chronicled the child’s case in the New England Journal of Medicine on Wednesday.

Pompe is an enzyme disease, and many of its youngest victims lack a gene that makes alpha-glucosidase or GAA, which is needed to break down glycogen, a stored form of sugar.

The resulting build up of glycogen damages the muscles, especially the heart and skeletal muscles.

Older Pompe patients often respond to enzyme replacement therapy, but many infants with the “CRIM negative” form of the disease quickly make antibodies to the enzyme and rarely see their first birthday.

Not so for Ira Brown of Minneapolis, whose symptoms first appeared at around five weeks of age.

Stymied by the poor prognosis of infants who develop the genetic disorder, Mendelsohn and colleagues decided to try suppress the child’s immune system to allow him to respond to the enzyme replacement treatment.

At 2-1/2, Brown is now the oldest survivor of the CRIM negative form of the disease.

Mendelsohn is hopeful the treatment will induce tolerance to enzyme-replacement therapy, so the Rituxan may one day be discontinued.

She said the treatment approach is being tried on other children and thinks it may work for other diseases, including hemophilia A and B, Gaucher’s disease and Fabry’s disease.

(Editing by Cynthia Osterman)


Related Posts:

NEW YORK (Reuters Health) - The immune-modulating drug leflunomide is effective as co-therapy with drugs that block the inflammation-producing protein TNF in people with rheumatoid arthritis, according to a report published this month. Rheumatoid arthritis, or RA, occurs when the immune system attacks the tissues that line the joints, leading to pain, inflammation and deformity. Rheumatoid

Full Post: Leflunomide effective as co-therapy in RA

HONG KONG (Reuters) - Researchers in Australia have designed a drug which appears effective in treating arthritis in mice, and they hope it can be used to treat diseases like rheumatoid arthritis and lupus in people. In an article published in Immunology and Cell Biology, the scientists said they zeroed in on a certain human receptor,

Full Post: New inhibitor drug seen for arthritis, lupus

LONDON (Reuters) - Joint damage suffered by people with rheumatoid arthritis may be caused by antibodies produced within the joint itself, British researchers said Tuesday in a study that may help development of new drugs. The study of joint biopsies from people with the condition which was then transplanted into mice found that tiny structures in

Full Post: Harmful enzyme may be key in rheumatoid arthritis

LOS ANGELES (Reuters) - A combination of Genentech Inc’s cancer drug Rituxan and chemotherapy reduces by 41 percent the risk of death or cancer progression, compared with chemotherapy alone, for patients with a common form of leukemia, the company said on Saturday. Results from the pivotal- or final-stage trial found that previously untreated patients given the

Full Post: Genentech drug boosts leukemia patient survival

NEW YORK (Reuters Health) - The health status of people with rheumatoid arthritis improved between 1994 and 2004, according to a new study. The researchers suggest this is most likely the result of better and more aggressive treatments. “Over the last decade, major changes have occurred in the provision of health care for patients with rheumatoid

Full Post: Rheumatoid arthritis therapy has improved steadily

Site Navigation

Most Read